Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that Buserelin can effectively inhibit gonadal activity in children with central precocious puberty over 18 months, potentially improving final height predictions with prolonged treatment.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

This study found that flutamide-induced liver toxicity in prostate cancer patients was very rare, occurring in only 0.18% of cases with clinical manifestations, and symptoms resolved after discontinuing the drug.

New hormonal therapies can help treat advanced prostate cancer but may cause testicular issues.

This study found that combining Flutamide and an LHRH agonist in adult male rats effectively inhibited prostatic growth and reduced androgen-sensitive prostatic activity markers to levels similar to castrated rats.

This review discusses hormonal manipulation for conditions like prostatic disorders and skin issues and highlights promising treatments like casodex and finasteride, but it reports no new clinical results.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

Hair loss is a common side effect of hormone treatments for cancer.

This review discusses the use of antiandrogens for various conditions like prostate cancer and highlights their potential benefits in remission rates and symptom improvement, but it reports no new clinical results.

This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This study found that the LH response to nafarelin effectively distinguished gonadotropin deficiency from constitutional delay of puberty, performing comparably to the sleep test and offering certain advantages.

This retrospective study found that serum hormone levels and MRI detection of ovarian nodules contributed to distinguishing virilizing ovarian tumors from ovarian stromal hyperthecosis in postmenopausal women, though histopathology remains crucial for diagnosis.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This review discusses the applications and research on fibroblast growth factors, including their use in wound healing, diabetes, and cancer, but it reports no new clinical results.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

This study suggests that synthetic steroid analogues or 5α-reductase modulation could be potential therapeutic strategies for nervous system disorders, but further research on their effects is necessary.

This study found that a low dose of flutamide, both alone and combined with an oral contraceptive, effectively reduced hirsutism in women, with the combination showing more lasting effects post-treatment.

This review discusses current treatment options for hirsutism, emphasizing the importance of combining therapies for better outcomes, but reports no new clinical findings.

This article discusses the importance of recognizing and distinguishing polycystic ovary syndrome from similar endocrine disorders, and reports no new clinical results.

This review summarizes current knowledge on the diagnosis and treatment of hirsutism but provides no new clinical results.

This review summarizes the structural and chemical characteristics of current and novel antiandrogenic drugs but reports no new clinical findings.

This review discusses the use of antiandrogen therapy in dermatology, covering treatments for conditions like acne, hirsutism, and androgenic alopecia but reports no new clinical findings.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This study found that bolandiol increased lean body mass and bone mineral density in castrate adult male rats, exhibiting tissue selectivity and acting through multiple receptor pathways with less potency compared to other androgens.

In this study, treatment with flutamide combined with a low-dose oral contraceptive significantly improved hirsutism in women with polycystic ovarian disease who did not respond to oral contraceptive treatment alone.

This review examines the negative effects of anabolic-androgenic steroid use on the male reproductive system, including impaired testosterone production, sperm production issues, and adverse metabolic consequences without reporting new clinical results.

This study found that adequate vitamin D status is necessary for metformin to effectively reduce prolactin levels in men with iatrogenic hyperprolactinemia, while improvements in glycemic control were observed across all vitamin D groups.